BioArctic

BioArctic Stock-Based Compensation

The Stock-Based Compensation (SBC) of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 24.04 M SEK. In the previous year, Stock-Based Compensation (SBC) was 19.33 M SEK — a change of 24.36% (higher).

Stock-Based Compensation

24.04 MSEK

YoY

24.36%

Last updated:

Stock-Based Compensation (SBC) of BioArctic is 2025 24.04 M SEK. Stock-Based Compensation (SBC) of BioArctic was 2024 19.33 M SEK. It decreases by 24.36% higher compared to the previous year.

The BioArctic Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
383,000.00 SEK
Jan 1, 2020
1.32 M SEK
Jan 1, 2021
1.57 M SEK
Jan 1, 2022
2.76 M SEK
Jan 1, 2023
16.14 M SEK
Jan 1, 2024
19.33 M SEK
Jan 1, 2025
24.04 M SEK
The BioArctic Stock-Based Compensation history
YEARStock-Based CompensationYoY
24.04 MSEK+24.36%
19.33 MSEK+19.81%
16.14 MSEK+484.67%
2.76 MSEK+76.02%
1.57 MSEK+18.88%
1.32 MSEK+244.39%
383,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Stock-Based Compensation (SBC) of BioArctic is 24.04 M SEK in 2025.

Stock-Based Compensation (SBC) of BioArctic changed from 19.33 M SEK to 24.04 M SEK, representing a 24.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) BioArctic since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioArctic

All Key Metrics — BioArctic